Immunotherapy combined with antiangiogenic agents in patients with advanced malignant pleural mesothelioma: A case report

被引：0

作者：

Xuan, Tian-Tian ^{[1
]}

Li, Guang-Yi ^{[2
]}

Meng, Si-Bo ^{[1
]}

Wang, Zhan-Mei ^{[1
]}

Qu, Lin-Li ^{[3
]}

机构：

[1] Shandong Univ, Qilu Hosp Qingdao, Cheeloo Coll Med, Dept Med Oncol, Qingdao 266035, Shandong, Peoples R China

[2] Shandong Univ, Qilu Hosp Qingdao, Cheeloo Coll Med, Dept Resp, Qingdao 266035, Shandong, Peoples R China

[3] Shandong Univ, Qilu Hosp Qingdao, Cheeloo Coll Med, Dept Med Oncol, 758 Hefei Rd, Qingdao 266035, Shandong, Peoples R China

来源：

WORLD JOURNAL OF CLINICAL CASES | 2022年 / 10卷 / 23期

关键词：

Pleural mesothelioma; Immune checkpoint inhibitor; Next-generation Sequencing; Immunerelated pneumonia; Immunotherapy rechallenge; Case report; OPEN-LABEL; CISPLATIN; PHASE-3;

D O I：

10.12998/wjcc.v10.i23.8284

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BACKGROUND Malignant pleural mesothelioma has limited therapeutic options and a poor outcome. Antiangiogenic agents might increase the efficacy of immunotherapy as second-line treatment of advanced-stage malignancies. CASE SUMMARY A patient with stage IIIB pleural mesothelioma received second-line treatment with a combination of pembrolizumab, bevacizumab and chemotherapy following standard chemotherapy under the guidance of second-generation sequencing. He achieved a partial response after four cycles of treatment with progression-free survival of 5 mo. Pembrolizumab was suspended due to grade 2 immunerelated pneumonia, which was resolved by oral glucocorticoids. However, disease progression was observed after immunotherapy rechallenge and anlotinib therapy. The patient had disease progression, multiorgan dysfuntion and died suddenly in October 2019. CONCLUSION The combination of immune checkpoint inhibitor, anti-angiogenic agents and chemotherapy showed effective response for advanced pleural mesothelioma, but with adverse reactions.

引用

页码：8284 / 8290

页数：7

共 23 条

[1] Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis [J].

Abu-Sbeih, Hamzah ;

Ali, Faisal S. ;

Naqash, Abdul Rafeh ;

Owen, Dwight H. ;

Patel, Sandipkumar ;

Otterson, Gregory A. ;

Kendra, Kari ;

Ricciuti, Biagio ;

Chiari, Rita ;

De Giglio, Andrea ;

Sleiman, Joseph ;

Funchain, Pauline ;

Wills, Beatriz ;

Zhang, Jiajia ;

Naidoo, Jarushka ;

Philpott, Jessica ;

Gao, Jianjun ;

Subudhi, Sumit K. ;

Wang, Yinghong .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (30) :2738-+

[2] Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial [J].

Alley, Evan W. ;

Lopez, Juanita ;

Santoro, Armando ;

Morosky, Anne ;

Saraf, Sanatan ;

Piperdi, Bilal ;

van Brummelen, Emilie .

LANCET ONCOLOGY, 2017, 18 (05) :623-630

[3] Second line therapy in malignant pleural mesothelioma: A systematic review [J].

Buikhuisen, Wieneke A. ;

Hiddingab, Birgitta I. ;

Baas, Paul ;

van Meerbeeck, Jan P. .

LUNG CANCER, 2015, 89 (03) :223-231

[4] Mesothelioma: Scientific clues for prevention, diagnosis, and therapy [J].

Carbone, Michele ;

Adusumilli, Prasad S. ;

Alexander, H. Richard, Jr. ;

Baas, Paul ;

Bardelli, Fabrizio ;

Bononi, Angela ;

Bueno, Raphael ;

Felley-Bosco, Emanuela ;

Galateau-Salle, Francoise ;

Jablons, David ;

Mansfield, Aaron S. ;

Minaai, Michael ;

de Perrot, Marc ;

Pesavento, Patricia ;

Rusch, Valerie ;

Severson, David T. ;

Taioli, Emanuela ;

Tsao, Anne ;

Woodard, Gavitt ;

Yang, Haining ;

Zauderer, Marjorie G. ;

Pass, Harvey, I .

CA-A CANCER JOURNAL FOR CLINICIANS, 2019, 69 (05) :402-429

[5] Hyperprogressive disease: recognizing a novel pattern to improve patient management [J].

Champiat, Stephane ;

Ferrara, Roberto ;

Massard, Christophe ;

Besse, Benjamin ;

Marabelle, Aurelien ;

Soria, Jean-Charles ;

Ferte, Charles .

NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (12) :748-762

[6] Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer [J].

Dolladille, Charles ;

Ederhy, Stephane ;

Sassier, Marion ;

Cautela, Jennifer ;

Thuny, Franck ;

Cohen, Ariel A. ;

Fedrizzi, Sophie ;

Chretien, Basile ;

Da-Silva, Angelique ;

Plane, Anne-Flore ;

Legallois, Damien ;

Milliez, Paul U. ;

Lelong-Boulouard, Veronique ;

Alexandre, Joachim .

JAMA ONCOLOGY, 2020, 6 (06) :865-871

[7] NCCN Guidelines® Insights Malignant Pleural Mesothelioma, Version 3.2016 Featured Updates to the NCCN Guidelines [J].

Ettinger, David S. ;

Wood, Douglas E. ;

Akerley, Wallace ;

Bazhenova, Lyudmila A. ;

Borghaei, Hossein ;

Camidge, David Ross ;

Cheney, Richard T. ;

Chirieac, Lucian R. ;

D'Amico, Thomas A. ;

Dilling, Thomas ;

Dobelbower, Michael ;

Govindan, Ramaswamy ;

Hennon, Mark ;

Horn, Leora ;

Jahan, Thierry M. ;

Komaki, Ritsuko ;

Lackner, Rudy P. ;

Lanuti, Michael ;

Lilenbaum, Rogerio ;

Lin, Jules ;

Loo, Billy W., Jr. ;

Martins, Renato ;

Otterson, Gregory A. ;

Patel, Jyoti D. ;

Pisters, Katherine M. ;

Reckamp, Karen ;

Riely, Gregory J. ;

Schild, Steven E. ;

Shapiro, Theresa A. ;

Sharma, Neelesh ;

Swanson, Scott J. ;

Stevenson, James ;

Tauer, Kurt ;

Yang, Stephen C. ;

Gregory, Kristina ;

Hughes, Miranda .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2016, 14 (07) :825-836

[8]

Goudar Ranjit K, 2008, Ther Clin Risk Manag, V4, P205

[9] Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial [J].

Herbst, Roy S. ;

Baas, Paul ;

Kim, Dong-Wan ;

Felip, Enriqueta ;

Perez-Gracia, Jose L. ;

Han, Ji-Youn ;

Molina, Julian ;

Kim, Joo-Hang ;

Arvis, Catherine Dubos ;

Ahn, Myung-Ju ;

Majem, Margarita ;

Fidler, Mary J. ;

de Castro, Gilberto, Jr. ;

Garrido, Marcelo ;

Lubiniecki, Gregory M. ;

Shentu, Yue ;

Im, Ellie ;

Dolled-Filhart, Marisa ;

Garon, Edward B. .

LANCET, 2016, 387 (10027) :1540-1550

[10] Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa [J].

Khan, Kabir A. ;

Kerbel, Robert S. .

NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (05) :310-324

← 1 2 3 →